Imunon, Inc. Proceeds from Stock Options Exercised
Imunon, Inc. (IMNN) reported Proceeds from Stock Options Exercised of $1.51 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-31.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromStockOptionsExercised · last filed 2022-03-31
- Imunon, Inc. proceeds from stock options exercised for the quarter ending 2021-03-31 was $4.72K.
- Imunon, Inc. proceeds from stock options exercised for the quarter ending 2020-12-31 was $0.00.
- Imunon, Inc. proceeds from stock options exercised for the quarter ending 2020-09-30 was $0.00.
- Imunon, Inc. proceeds from stock options exercised for the quarter ending 2013-12-31 was $0.00, a 100.00% decline year-over-year.
- Imunon, Inc. proceeds from stock options exercised for fiscal 2021 was $1.51M, a 305.67% increase from fiscal 2020.
- Imunon, Inc. proceeds from stock options exercised for fiscal 2020 was $371.89K.
- Imunon, Inc. proceeds from stock options exercised for fiscal 2015 was $0.00.
- Imunon, Inc. proceeds from stock options exercised for fiscal 2014 was $0.00, a 100.00% decline from fiscal 2013.
| Period end | Proceeds from Stock Options Exercised 3 month | Proceeds from Stock Options Exercised 6 month | Proceeds from Stock Options Exercised 9 month | Proceeds from Stock Options Exercised 12 month | Proceeds from Stock Options Exercised 24 month |
|---|---|---|---|---|---|
| 2021-12-31 | $1.51M 10-K · filed 2022-03-31 | ||||
| 2021-03-31 | $4.72K 10-Q · filed 2021-05-14 | $4.72K derived: sum of 2 quarters · filed 2021-05-14 | $4.72K derived: sum of 3 quarters · filed 2021-05-14 | ||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-19 | $0.00 derived: sum of 2 quarters · filed 2021-03-19 | $371.89K 10-K · filed 2021-03-19 | ||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16 | $371.89K 10-Q · filed 2020-11-16 | |||
| 2020-06-30 | $371.89K 10-Q · filed 2020-08-14 | ||||
| 2016-12-31 | $0.00 10-K · filed 2017-03-24 | ||||
| 2015-12-31 | $0.00 10-K · filed 2016-03-30 | ||||
| 2014-12-31 | $0.00 10-K · filed 2016-03-30 | ||||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-30 | $2.71K derived: sum of 2 quarters · filed 2016-03-30 | $9.18K derived: sum of 3 quarters · filed 2016-03-30 | $184.05K 10-K · filed 2016-03-30 | |
| 2013-09-30 | $2.71K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | $9.18K derived: sum of 2 quarters · filed 2014-11-10 | $184.05K 10-Q · filed 2014-11-10 | $776.73K derived: sum of 4 quarters · filed 2015-03-12 | |
| 2013-06-30 | $6.47K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | $181.34K 10-Q · filed 2014-08-07 | $774.02K derived: sum of 3 quarters · filed 2015-03-12 | $678.56K derived: sum of 4 quarters · filed 2015-03-12 | |
| 2013-03-31 | $174.87K 10-Q · filed 2014-05-08 | $767.55K derived: sum of 2 quarters · filed 2015-03-12 | $672.09K derived: sum of 3 quarters · filed 2015-03-12 | ||
| 2012-12-31 | $592.68K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | $497.22K derived: sum of 2 quarters · filed 2015-03-12 | $697.22K 10-K · filed 2015-03-12 | ||
| 2012-09-30 | -$95.46K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | $104.54K 10-Q · filed 2013-11-12 | |||
| 2012-06-30 | $200.00K 10-Q · filed 2013-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |